| Literature DB >> 27500954 |
Lien Anh Ha Do1,2, Juliet E Bryant1,3, Anh Tuan Tran4, Bach Hue Nguyen4, Thi Thu Loan Tran5, Quynh Huong Tran5, Quoc Bao Vo5, Nguyen Anh Tran Dac5, Hong Nhien Trinh4, Thi Thanh Hai Nguyen4, Bao Tinh Le Binh4, Khanh Le4, Minh Tien Nguyen4, Quang Tung Thai4, Thanh Vu Vo4, Ngoc Quang Minh Ngo4, Thi Kim Huyen Dang5, Ngoc Huong Cao5, Thu Van Tran5, Lu Viet Ho5, Jeremy Farrar1, Menno de Jong1,3,6, H Rogier van Doorn1,3.
Abstract
BACKGROUND: Despite a high burden of respiratory syncytial virus (RSV) infections among children, data on demographic and clinical characteristics of RSV are scarce in low and middle income countries. This study aims to describe the viral etiologies, the demographic, epidemiological, and clinical characteristics of children under two years of age who were hospitalized with a lower respiratory tract infections (LRTI), focusing on RSV (prevalence, seasonality, subgroups, viral load) and its association with disease severity.Entities:
Mesh:
Year: 2016 PMID: 27500954 PMCID: PMC4976934 DOI: 10.1371/journal.pone.0160606
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical score index*.
| Clinical symptoms | Score given |
|---|---|
| Mild fever (37.5 to 38.5°C) | 1 |
| High fever (>38.5°C) | 2 |
| Respiratory rates from 45–59 per min | 1 |
| Respiratory rates from 60–74 per min | 2 |
| Respiratory rates from > 75 per min | 3 |
| Chest indrawing | 2 |
| Wheezing | 1 |
| Stridor | 1 |
| Apnea | 3 |
| Cyanosis | 3 |
| Low SpO2 (<92) or under oxygen | 3 |
| NCPAP or CPAP or ventilated during hospitalization | 4 |
| High ALT | 1 |
| High AST | 1 |
* A higher clinical score indicates more severe disease.
** Liver enzymes ALT and AST levels were considered to be elevated if above 36 IU/l and above 58 IU/l, respectively.
Fig 1Number of cases enrolled and total numbers of LRTI children hospitalized in two referral pediatric hospitals in southern Vietnam, May 2009 to December 2010.
A total of 106/632 (17%)of cases met at least one clinical criterion for severe disease, and 43% (271/632) were hospitalized for >7 days. Among the children requiring supplemental oxygen or ventilatory support, 16/93 (17%) received NCPAP, 2/93 (2%) were intubated.
Viral single and co-infections among all enrolled patients.
| VIRUSES | All | Single infections | Co- infection | p-value |
|---|---|---|---|---|
| N = 632 | N = 375 | N = 199 | ||
| RSV, n(%) | 302 (48) | 201 (54) | 101 (51) | 0.9 |
| RSV A, n(%) | 156 (25) | 101 (27) | 55 (28) | 0.9 |
| Median log copies/ml RSVA (IQR) | 7.5 (6.7–8.2) | 7.7 (6.7–8.1) | 7.4 (6.3–8.2) | 0.2 |
| RSV B, n(%) | 139 (22) | 93 (25) | 46 (23) | 0.7 |
| Median log copies/ml RSVB (IQR) | 7.6 (6.9–8.2) | 7.7 (7.1–8.2) | 7.5 (6.6–8.0) | 0.2 |
| Flu, n(%) | 16 (3) | 8 (2) | 8 (4) | 0.2 |
| Flu A, n(%) | 10 (2) | 5 (1) | 5 (3) | 0.3 |
| Median Cp-value flu A (IQR) | 31 (29–34) | 30 (30–31) | 33 (29–35) | 0.5 |
| InflV B, n(%) | 6 (1) | 3 (1) | 3 (2) | 0.4 |
| Median Cp-value flu B (IQR) | 31 (29–33) | 32 (29–33) | 30 (20–34) | 0.8 |
| AdV, n(%) | 37(6) | 3 (1) | 34 (17) | |
| Median Cp-value AdV (IQR) | 35 (31–36) | 35 (30–35) | 34 (31–36) | 0.8 |
| EnV, n(%) | 65 (10) | 2 (1) | 63 (32) | |
| Median Cp-value EnV (IQR) | 33 (30–35) | 32 (29–35) | 33 (30–35) | 0.8 |
| MPV, n(%) | 30 (5) | 17 (5) | 13 (7) | 0.3 |
| Median Cp-value MPV (IQR) | 27 (24–36) | 26 (23–29) | 36 (27–36) | |
| RV, n(%) | 206 (33) | 87 (23) | 119 (60) | |
| Median Cp-value RV (IQR) | 27 (25–30) | 26 (24–28) | 28 (26–31) | |
| PIV-1, n(%) | 9 (1) | 5 (1) | 4 (2) | 0.5 |
| Median Cp-value PIV-1 (IQR) | 27 (25–30) | 28 (26–30) | 26 (22–32) | 0.5 |
| PIV-2, n(%) | 14 (2) | 4 (1) | 10 (5) | |
| Median Cp-value PIV-2 (IQR) | 26 (23–30) | 22 (22–23) | 33 (26–36) | |
| PIV-3, n(%) | 47 (7) | 18 (5) | 29 (15) | |
| Median Cp-value PIV-3 (IQR) | 29 (24–35) | 25 (23–32) | 32 (25–37) | |
| PIV-4, n(%) | 25 (4) | 13 (4) | 12 (6) | 0.2 |
| Median Cp-value PIV-4 (IQR) | 31 (27–34) | 29 (25–33) | 33 (30–35) | |
| hCoV, n(%) | 25 (4) | 8 (2) | 17 (9) | |
| Median Cp-value hCoV (IQR) | 29 (27–32) | 27 (24–29) | 30 (28–33) | 0.1 |
| PeV, n(%) | 12 (2) | 2 (1) | 10 (5) | |
| Median Cp-value PeV (IQR) | 28 (26–29) | 28 (26–31) | 28 (27–29) | 0.7 |
| BoV, n(%) | 42 (7) | 7 (2) | 35 (18) | |
| Median Cp-value BoV (IQR) | 29 (25–33) | 23 (22–30) | 30 (25–35) | 0.1 |
P-value was calculated between single infections and co-infections groups,
(1) Mann-Whitney test,
(2) Fisher’s exact test,
N.A: not applicable.
Factors independently predicting disease severity or long hospitalization among LRTI hospitalized children and among RSV-infected children.
| Independent predictors | Outcome measure | |||||||
|---|---|---|---|---|---|---|---|---|
| Disease severity | Long hospitalization | |||||||
| LRTI children (N = 605) | RSV-infected children (N = 293) | LRTI children (N = 605) | RSV-infected children (N = 293) | |||||
| OR(95%) | P-value | OR(95%) | P-value | OR(95%) | P-value | OR(95%) | P-value | |
| 0.89 (0.85–0.94) | 0.89 (0.81–0.95) | 0.93 (0.90–0.96) | 0.95 (0.91–1.00) | |||||
| 0.83 (0.51–1.36) | 0.46 | 0.92 (0.44–1.90) | 0.83 | 1.17 (0.81–1.69) | 0.39 | 1.41 (0.82–2.43) | 0.21 | |
| 1.06 (0.47–2.39) | 0.88 | 1.20 (0.37–3.89) | 0.75 | 1.79 (0.96–3.29) | 0.06 | 2.34 (0.91–5.99) | 0.07 | |
| 0.99 (0.53–1.83) | 0.96 | 0.43 (0.13–1.42) | 0.17 | 2.49 (1.59–3.92) | 1.29 (0.61–2.72) | 0.49 | ||
| 1.41 (0.87–2.26) | 0.15 | 1.98 (0.99–3.94) | 1.15 (0.81–1.64) | 0.42 | 1.26 (0.74–2.14) | 0.38 | ||
| 1.31 (0.81–2.11) | 0.26 | 1.24 (0.63–2.45) | 0.53 | 0.92 (0.66–1.31) | 0.67 | 1.31 (0.79–2.17) | 0.28 | |
| 1.04 (0.95–1.15) | 0.88 | 1.03 (0.89–1.10) | 0.63 | 1.02 (0.97–1.11) | 0.49 | 0.95 (0.85–1.07) | 0.42 | |
| 3.82 (2.29–6.36) | 4.84 (2.27–10.30) | 1.77 (1.25–2.51) | 2.66 (1.58–4.47) | |||||
| 1.39 (0.82–2.39) | 0.22 | 0.60 (0.30–1.17) | 0.13 | 0.79 (0.54–1.15) | 0.22 | 0.79 (0.48–1.30) | 0.36 | |
| 2.31 (1.17–4.59) | 0.30 (0.08–1.07) | 0.06 | 1.1 (0.63–1.84) | 0.77 | 1.17 (0.58–2.35) | 0.65 | ||
| N.A | N.A | 1.03 (0.78–1.35) | 0.85 | N.A | N.A | 1.14 (0.93–1.39) | 0.19 | |
(1) RSV single infection factor was used for the model of the whole population and RSV subgroup (RSV B versus A) was used for the model of RSV-infected patients
(2) RV single infection factor for the model of the whole population and RV co-infection with RSV for the model of RSV-infected patients
N.A: not applicable
Viral etiologies and age group.
| Virus name | Age groups | ||||
|---|---|---|---|---|---|
| <2m | 2m-6m | 7m-11m | 12m–24m | Total | |
| n = 41 | n = 277 | n = 174 | n = 140 | N = 632 | |
| RSV positive, n(%) | 22 (54) | 152 (55) | 74 (43) | 54 (39) | 302 (48) |
| RSVA, n(%) | 13 (32) | 84 (30) | 31 (18) | 28 (20) | 156 (25) |
| RSV B, n(%) | 9 (22) | 63 (23) | 42 (27) | 25 (18) | 139 (22) |
| Both RSVA and RSVB, n(%) | 0 (0) | 5 (2) | 1 (1) | 1 (1) | 7 (1) |
| Flu V positive, n(%) | 0 (0) | 6 (2) | 5 (3) | 5 (4) | 16 (3) |
| Flu A, n(%) | 0 (0) | 4 (1) | 4 (2) | 2 (1) | 10 (2) |
| Flu B, n(%) | 0 (0) | 2 (1) | 1 (1) | 3 (2) | 6 (1) |
| AdV, n(%) | 1 (2) | 11 (4) | 15 (9) | 10 (7) | 37 (6) |
| EnV, n(%) | 5 (12) | 29 (10) | 17 (10) | 14 (10) | 65 (10) |
| MPV, n(%) | 3 (7) | 9 (3) | 9 (5) | 9 (6) | 30 (5) |
| RV, n(%) | 10 (24) | 91 (33) | 61(35) | 44 (31) | 206 (33) |
| PIV-1, n(%) | 0 (0) | 5 (2) | 2 (1) | 2 (1) | 9 (1) |
| PIV-2, n(%) | 0 (0) | 8 (3) | 5 (3) | 1 (1) | 14 (2) |
| PIV-3, n(%) | 2 (5) | 16 (6) | 14 (8) | 15 (11) | 47 (7) |
| PIV-4, n(%) | 0 (0) | 12 (4) | 7 (4) | 6 (4) | 25 (4) |
| CoV, n(%) | 1 (2) | 14 (5) | 6 (3) | 4 (3) | 25 (4) |
| PeV, n(%) | 0 (0) | 9 (3) | 2 (1) | 1 (1) | 12 (2) |
| BoV, n(%) | 3 (7) | 13 (5) | 12 (7) | 14 (10) | 42 (7) |
| 26 (63) | 160 (58) | 104 (60) | 85 (61) | 375 (59) | |
| 9 (22) | 94 (34) | 55 (31) | 41 (29) | 199 (31) | |
| 6 (15) | 23 (8) | 15 (9) | 14 (10) | 58 (9) | |
Comparison of demographic and clinical characteristics among patients with RSV, RV, MPV and PIV-3.
| Single RSV infection | Single RV infection | Single MPV infection | Single PIV-3 infections | ||||
|---|---|---|---|---|---|---|---|
| N = 201 | N = 87 | p-value | N = 17 | p-value | N = 18 | p-value | |
| Median age in months (IQR) | 6 (3–10) | 8 (4–12) | 0.09 | 11 (8–14) | 9 (6–16) | ||
| Infant (less than 2months), n(%) | 15 (7) | 5 (6) | 2 (12) | 2 (11) | |||
| Infant (2 to 6months), n(%) | 103 (51) | 31 (36) | 2 (12) | 3 (17) | |||
| Infant (7 to 11months), n(%) | 47 (24) | 31 (36) | 6 (35) | 7 (39) | |||
| Infant (12 to 24months), n(%) | 36 (18) | 20 (23) | 7 (41) | 6 (33) | |||
| Male, n(%) | 138 (69) | 62 (71) | 0.7 | 12 (71) | 0.9 | 10 (56) | 0.3 |
| Median number of household members (IQR) | 4 (4–6) | 4 (4–6) | 0.7 | 4 (3–5) | 0.3 | 4 (3–6) | 0.4 |
| Living with smokers, n (%) | 102/196 (52) | 51/86 (59) | 0.3 | 5 (29) | 0.07 | 12 (67) | 0.2 |
| Median birth weight (kg) (IQR) | 3.9 (2.2–3.3) | 2.7 (2.3–3.2) | 0.3 | 3.3 (2.8–3.8) | 0.5 | 3 (2.6–3.4) | 0.7 |
| Breastfeeding, n(%) | 148/197 (75) | 59/86 (69) | 0.3 | 16 (94) | 0.07 | 13 (72) | 0.8 |
| Premature birth, n(%) | 20/199 (10) | 14/85 (16) | 0.1 | 0/16 (0) | N.A | 1/17 (6) | 0.5 |
| Daycare, n (%) | 25/197 (13) | 10/84 (12) | 0.9 | 2/16 (13) | 1.0 | 5/18 (28) | 0.08 |
| Previous hospitalization with respiratory illness, n (%) | 22 (11) | 23 (26) | 2 (12) | 0.9 | 3 (17) | 0.5 | |
| Other household members sick at home, n (%) | 76/197 (39) | 36/85 (42) | 0.6 | 5 (29) | 0.5 | 5 (28) | 0.4 |
| Fast breathing, n(%) | 166 (83) | 75 (86) | 0.4 | 14 (82) | 1.0 | 14 (78) | 0.6 |
| Cyanosis, n(%) | 6 (3) | 3 (4) | N.A | 0 (0) | N.A | 0 (0) | N.A |
| Chest indrawings, n(%) | 193 (96) | 81 (94) | 0.3 | 15 (88) | 0.1 | 15 (83) | 0.01 |
| Stridor, n(%) | 1 (1) | 1 (1) | 0.5 | 0 (0) | N.A | 0 (0) | N.A |
| Wheezing, n(%) | 192 (96) | 76 (88) | 16 (94) | 0.8 | 17 (94) | 0.8 | |
| Fever (>37.5°C), n(%) | 112 (56) | 50 (57) | 0.8 | 7 (41) | 0.2 | 6 (33) | 0.07 |
| Fever (≥ 38.5°C), n(%) | 46 (23) | 13 (15) | 0.1 | 5 (29) | 0.5 | 2 (11) | 0.2 |
| Rash, n(%) | 2 (1) | 3 (3) | 0.1 | 0 (0) | N.A | 1 (6) | 0.1 |
| Runny nose, n(%) | 181 (91) | 70 (81) | 15 (88) | 0.8 | 17 (94) | 0.5 | |
| Low SpO2, n(%) | 19/140 (14) | 6/60 (10) | 0.5 | 1/14 (7) | 0.5 | 1/17 (6) | 0.4 |
| Median of duration of hospitalization (IQR) | 6 (5–7) | 6 (5–8) | 6 (4–7) | 0.9 | 6 (5–7) | 0.9 | |
| Duration of hospitalization ≥ 7 days, n(%) | 77 (38) | 43 (49) | 0.08 | 7 (41) | 0.8 | 7 (39) | 1.0 |
| High ALT, n(%) | 54 (27) | 16 (18) | 0.1 | 2 (12) | 0.2 | 3 (17) | 0.3 |
| High AST, n(%) | 44 (22) | 9 (10) | 4 (23) | 0.9 | 3 (17) | 0.6 | |
| Median of number of white cells in blood (K/mm3) (IQR) | 10 (8–14) | 13 (11–17) | 11 (9–13) | 0.8 | 11 (8–17) | 0.6 | |
| Severe cases, n(%) | 36 (18) | 22 (25) | 0.2 | 3 (18) | 1.0 | 3 (17) | 1.0 |
| Median of clinical score (IQR) | 6 (4–7) (n = 186) | 5 (4–7) (n = 80) | 0.5 | 5 (4–6) | 0.4 | 4.5 (4–6) | |
| Bronchiolitis, n(%) | 162 (81) | 65 (75) | 0.3 | 10 (59) | 0.06 | 9 (50) | 0.005 |
| Antimicrobial agents, n(%) | 169 (84) | 62 (71) | 17 (100) | 0.07 | 17 (94) | 0.2 | |
| Corticosteroids, n(%) | 9 (4) | 6 (7) | 0.4 | 1 (6) | 0.8 | 0 (0) | N.A |
| Bronchodilators, n(%) | 168 (84) | 67 (77) | 0.2 | 9 (52) | 10 (56) | ||
| Supplemental oxygen, n(%) | 31 (15) | 21 (24) | 0.08 | 2 (12) | 0.7 | 2 (11) | 0.6 |
| Full recovery, n(%) | 119/195 (61) | 46/81 (57) | 0.5 | 11 (73) | 0.8 | 11 (65) | 0.9 |
| Severe cases, n(%) | 36 (18) | 22 (25) | 0.2 | 3 (18) | 1.0 | 3 (17) | 0.9 |
| Death, n(%) | 0 (0) | 1(1) | N.A | 0 (0) | N.A | 0 (0) | N.A |
p-values were based on comparison with children having RSV single infections.
(1) Mann-Withney test,
(2) Fisher’s exact test,
N.A: not applicable
Fig 2RSV, RSV subgroups, other viruses and severe cases distribution.